The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
An apparatus for automatic discriminating and reckoning of peags, of different denominations, is disclosed. Said apparatus broadly comprises: an at least a conveying member (11); an at least a feeding member (12); an at least a smoothening member (18); an at least a pick and place member (13); a first receptacle (16); a second receptacle (17); an at least an object detecting member (14); an at least a control member (15); and a displaying member. Method of working of said apparatus is also disclosed. The disclosed apparatus may be implemented, in various environments, including, but not limited to: temples. The disclosed apparatus offers at least the following advantages: is efficient; is accurate; saves time; reduces manpower, thereby, reducing costs; and reduces redundancy errors.
The present disclosure relates to V and F-codoped cobalt hydroxide nanowires electrocatalysts V—Co(OH)2 comprises vanadium (V) at less stable 4+ oxidation state and fluoride (F) ions codoped directly on carbon cloth electrode. The V—Co(OH)2 produces excellent oxygen evolution reaction (OER) activity in alkaline conditions. The present disclosure also relates to a method of fabrication of the V and F-codoped cobalt hydroxide nanowires electrocatalysts V—Co(OH)2 comprising vanadium (V) at less stable 4+ oxidation state and fluoride (F) ions codoped directly on carbon cloth electrode by hydrothermal reaction.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
C25B 11/056 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the substrate or carrier material consisting of textile or non-woven fabric
8444)(DMF)), and a method of preparing the same. More specifically, the present disclosure relates to a method of using said surface-coated porous ZnTPA MOF for selectively removing organic cationic dyes from an aqueous medium containing mix of dyes. Formula I
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
An anti-infective agent for use in treatment of candidiasis is disclosed. A method of treating candidiasis is also disclosed. Said method comprises step of: administering an anti-infective agent, at a dosage that ranges between about 90 nM and about 200 nM. The disclosed anti-infective agent offers at least the advantage of inhibiting Candida species morphogenesis, at very low concentrations.
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A nanocomposite for treating bacterial urinary tract infections is disclosed. Said nanocomposite broadly comprises: an about 10 mg/mL of zinc oxide nanoparticles; an about 2 mg/mL of type-A procyanidin; and methanol. Said zinc oxide nanoparticles are of sizes that range between about 20 nm and about 80 nm. A method of synthesising said nanocomposite is also disclosed. The disclosed nanocomposite and method offer at least the following synergistic advantages and effects: low MIC50 values; good bacterial biofilm inhibiting properties; eradicate pre-formed bacterial biofilms and dispersed bacterial cells; eradicate adhered bacterial cells; and superior safety profiles. The disclosed nanocomposite may be directly coated, onto catheters, for treating bacterial urinary tract infections. Alternatively, or in addition, it may also be part of a kit, for treating bacterial urinary tract infections.
C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
The present invention relates to metal organic framework (MOF) compounds. Specifically, the present invention relates to a metal organic framework compounds based on nickel, cobalt and copper metals and method of preparation thereof. The metal organic framework compounds of present invention exhibit enhanced electrocatalytic oxygen evolution reaction (OER) activity without using any additives or complimentary conducting materials.
B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61K 9/00 - Medicinal preparations characterised by special physical form
9.
AGGREGATION INDUCED EMISSIVE FLUOROPHORES (AIEGENS) INTERCONNECTED THROUGH NONCONJUGATED SPACER, PROCESS FOR PREPARATION AND APPLICATIONS THEREOF
An aggregation induced emissive fluorophore (AIEgen) interconnected through nonconjugated spacer having a structural formula selected from: formulas (1), (2), or (3) wherein, (a); and X is (b), (c), (d), (e), (f), (g) or (h). The present disclosure further provides a process for preparing the AIEgen interconnected through nonconjugated spacer and applications thereof.
C07C 217/92 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the nitrogen atom of at least one of the amino groups being further bound to a carbon atom of a six-membered aromatic ring
patents
